The designation on the cover of this publication, "USP NF 2015," is for ease of identification only. The publication contains two separate compendia: The United States Pharmacopeia, Thirty-Eighth Revision, and The National Formulary, Thirty-Third Edition.
SIX-MONTH IMPLEMENTATION GUIDELINE

The *United States Pharmacopeia–National Formulary* and its supplements become official six months after being released to the public. The *USP–NF*, which is released on November 1 of each year, becomes official on May 1 of the following year. This six-month implementation timing gives users more time to bring their methods and procedures into compliance with new and revised *USP–NF* requirements.

The table below describes the official dates of the *USP–NF* and its supplements. The 2014 *USP 37–NF 32*, and its supplements, *Interim Revision Announcements* (IRAs) and *Revision Bulletins* to that edition, will be official until May 1, 2015, at which time the *USP 38–NF 33* becomes official.

<table>
<thead>
<tr>
<th>Publication</th>
<th>Release Date</th>
<th>Official Date</th>
<th>Official Until</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>USP 38–NF 33</em></td>
<td>November 1, 2014</td>
<td>May 1, 2015</td>
<td>May 1, 2016 (except as superseded by supplements, IRAs, and Revision Bulletins)</td>
</tr>
<tr>
<td>First Supplement to the <em>USP 38–NF 33</em></td>
<td>February 1, 2015</td>
<td>August 1, 2015</td>
<td>May 1, 2016 (except as superseded by Second Supplement, IRAs, and Revision Bulletins)</td>
</tr>
<tr>
<td>Second Supplement to the <em>USP 38–NF 33</em></td>
<td>June 1, 2015</td>
<td>December 1, 2015</td>
<td>May 1, 2016 (except as superseded by IRAs and Revision Bulletins)</td>
</tr>
<tr>
<td><em>USP 39–NF 34</em></td>
<td>November 1, 2015</td>
<td>May 1, 2016</td>
<td>May 1, 2017 (except as superseded by supplements, IRAs, and Revision Bulletins)</td>
</tr>
</tbody>
</table>

The table below gives the details of the IRAs that will apply to *USP 38–NF 33*.

<table>
<thead>
<tr>
<th>IRA</th>
<th>PF Posting Date</th>
<th>Comment Due Date</th>
<th>IRA Posting Date</th>
<th>IRA Official Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>41(3)</td>
<td>May 1, 2015</td>
<td>July 31, 2015</td>
<td>September 26, 2015</td>
<td>November 1, 2015</td>
</tr>
</tbody>
</table>

*Revision Bulletins* published on the USP website become official on the date specified in the *Revision Bulletin*.

NOTICE AND WARNING

**Concerning U.S. Patent or Trademark Rights**—The inclusion in *The United States Pharmacopeia* or in the *National Formulary* of a monograph on any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner.

**Concerning Use of USP or NF Text**—Attention is called to the fact that *USP* and *NF* text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Secretary of the USPC Board of Trustees.
Contents

VOLUME 1

Mission Statement and Preface ........ vii

People 2010–2015 Revision Cycle ........ xv

Officers ........................................ xv
Board of Trustees ............................... xv
Council of Experts .............................. xv
Expert Committees ............................. xvi
Advisory Groups ............................... xxiv
In Memoriam .................................. xxiv

Members of the United States Pharmacopeial Convention, as of May 31, 2014 ........ xxv

2013 Recognition of Monograph and Reference Material Donors ........ xxi

Articles of Incorporation .................. xxxiv
USP Governance ............................... xxxv
Bylaws ......................................... xxxv
Rules and Procedures ........................ xxxv
USP Policies .................................. xxxv

Admissions ....................................... xxxix
Articles Admitted to USP 38 by Supplement ............................................ xxxix
New Articles Appearing in USP 38 That Were Not Included in USP 37 Including Supplements ......................... xli

Articles Included in USP 37 But Not Included in USP 38 ........................ xli
Annotated List ................................. xlii

Notices

General Notices and Requirements ........ 1

General Chapters

See page 49 for detailed contents

General Tests and Assays .................. 53
General Requirements for Tests and Assays .... 53
Apparatus for Tests and Assays ......... 96
Microbiological Tests ..................... 100
Biological Tests and Assays ............. 133
Chemical Tests and Assays ............. 216
Physical Tests and Determinations ...... 388
General Information ...................... 699
Dietary Supplements .................... 1751

Reagents, Indicators, and Solutions ........ 1809

Reagent Specifications .................... 1814
Indicators and Indicator Test Papers .... 1881
Solutions ................................. 1884
Buffer Solutions ............................ 1884
Colorimetric Solutions .................... 1885
Test Solutions .............................. 1886
Volumetric Solutions .................... 1894
Chromatographic Columns ................ 1902
Reference Tables
- Containers for Dispensing Capsules and Tablets ............................................. 1907
- Description and Relative Solubility of USP and NF Articles .......................... 1917
- Approximate Solubilities of USP and NF Articles .......................................... 1976
- Atomic Weights ................................................................................................. 1984
- Atomic Masses .................................................................................................. 1987
- Alcohometric Table ............................................................................................ 1989
- Intrinsic Viscosity Table ...................................................................................... 1991
- Thermometric Equivalents .................................................................................. 1993

Index
- Combined Index to USP 38 and NF 33 ............................................................. 1-1

VOLUME 2

Guide to General Chapters .......................................................... vii

Notices
- General Notices and Requirements ................................................................. xi

USP 38

Monographs
- Official Monographs for USP 38, A–I ............................................................. 1995

Index
- Combined Index to USP 38 and NF 33 ............................................................. 1-1

VOLUME 3

Guide to General Chapters .......................................................... vii

Notices
- General Notices and Requirements ................................................................. xi

USP 38

Monographs
- Official Monographs for USP 38, J–Z ............................................................. 3999

Index
- Combined Index to USP 38 and NF 33 ............................................................. 1-1

VOLUME 4

Guide to General Chapters .......................................................... vii

Notices
- General Notices and Requirements ................................................................. xi

Dietary Supplements
- Official Monographs .......................................................................................... 5865

Index
- Combined Index to USP 38 and NF 33 ............................................................. 1-1
NF 33

Admissions

Articles Admitted to NF 33 by Supplement 6491

New Articles Appearing in NF 33 That Were Not Included in NF 32 Including Supplements 6491

New Articles Appearing in NF 33 6491

Annotated List 6492

Excipients

USP and NF Excipients, Listed by Category 6493

Monographs

Official Monographs for NF 33 6503

Combined Index to USP 38 and NF 33 1-1
Guide to General Chapters

(For complete alphabetical list of all general chapters in this Pharmacopeia, see under “General chapters” in the index.)

GENERAL TESTS AND ASSAYS

General Requirements for Tests and Assays

(1) Injections .................................................. 53
(2) Oral Drug Products—Product Quality Tests .......... 66
(3) Topical and Transdermal Drug Products—
    Product Quality Tests .................................... 71
(4) Mucosal Drug Products—Product Quality Tests .... 76
(5) Inhalation and Nasal Drug Products—
    General Information and Product Quality Tests ..... 80
(7) Labeling .................................................. 87
(11) USP Reference Standards ................................. 93

Apparatus for Tests and Assays

(17) Prescription Container Labeling ......................... 96
(21) Thermometers ........................................... 98
(31) Volumetric Apparatus .................................. 99
(41) Balances .................................................. 99

Microbiological Tests

(51) Antimicrobial Effectiveness Testing ................. 100
(55) Biological Indicators—Resistance Performance
    Tests ...................................................... 103
(61) Microbiological Examination of Nonsterile
    Products: Microbial Enumeration Tests ............... 106
(62) Microbiological Examination of Nonsterile
    Products: Tests for Specified Microorganisms ..... 112
(63) Mycoplasma Tests ..................................... 120
(71) Sterility Tests .......................................... 125

Biological Tests and Assays

(81) Antibiotics—Microbial Assays ......................... 133
(85) Bacterial Endotoxins Test ............................. 151
(87) Biological Reactivity Tests, In Vitro ................ 156
(88) Biological Reactivity Tests, In Vivo ................ 158
(89) Enzymes Used as Ancillary Materials in
    Pharmaceutical Manufacturing ....................... 164
(90) Fetal Bovine Serum—Quality Attributes and
    Functionality Tests .................................... 167
(91) Calcium Pantothenate Assay .......................... 171
(92) Growth Factors and Cytokines Used in Cell
    Therapy Manufacturing ................................ 172
(111) Design and Analysis of Biological Assays ......... 176
(115) Dexpanthenol Assay .................................. 191
(121) Insulin Assays ........................................ 193
(121.1) Physico-chemical Analytical Procedures
    for Insulins ............................................. 195
(123) Glucagon Biodentity Tests ........................... 198
(124) Erythropoietin Bioassays ............................ 200
(126) Somatropin Biodentity Tests ......................... 202
(130) Protein A Quality Attributes ......................... 204

(151) Pyrogen Test ........................................ 211
(161) Transfusion and Infusion Assemblies and Similar
    Medical Devices ......................................... 212
(171) Vitamin B₁₂ Activity Assay ........................ 213

Chemical Tests and Assays

Identification Tests

(181) Identification—Organic Nitrogenous Bases ........ 216
(191) Identification Tests—General ........................ 216
(193) Identification—Tetracyclines ........................ 219
(197) Spectrophotometric Identification Tests .......... 220
(201) Thin-Layer Chromatographic Identification
    Test ...................................................... 221

Limit Tests

(206) Aluminum .............................................. 222
(207) Test for 1,6-Anhydro Derivative for Enoxaparin
    Sodium .................................................. 223
(208) Anti-Factor Xa and Anti-Factor IIa Assays for
    Unfractionated and Low Molecular Weight
    Heparins ................................................. 228
(209) Low Molecular Weight Heparin Molecular
    Weight Determinations ................................ 232
(211) Arsenic ................................................ 233
(221) Chloride and Sulfate ................................ 235
(223) Dimethylaniline ....................................... 236
(226) 4-Epianhydrotetracycline ............................ 236
(227) 4-Aminophenol in Acetaminophen-Containing
    Drug Products .......................................... 237
(228) Ethylene Oxide and Dioxane ........................ 238
(231) Heavy Metals ......................................... 241
(232) Elemental Impurities—Limits ......................... 243
(233) Elemental Impurities—Procedures ................. 245
(241) Iron ..................................................... 249
(251) Lead ..................................................... 250
(261) Mercury ................................................. 251
(267) Porosimetry by Mercury Intrusion .................. 253
(268) Porosity By Nitrogen Adsorption–Desorption .... 256
(271) Readily Carbonizable Substances Test ............. 260
(281) Residue on Ignition .................................. 260
(291) Selenium ............................................... 261

Other Tests and Assays

(301) Acid-Neutralizing Capacity ......................... 261
(311) Alginates Assay ...................................... 262
(341) Antimicrobial Agents—Content ..................... 264
(345) Assay for Citric Acid/Citrate and Phosphate ...... 267
(351) Assay for Steroids .................................. 268
(361) Barbiturate Assay ................................... 268
(371) Cobalamin Radiotracer Assay ....................... 268
Physical Tests and Determinations

(601) Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests ............................................. 388
(602) Propellants ........................................................................ 414
(603) Topical Aerosols ................................................................ 415
(604) Leak Rate .......................................................................... 416
(610) Alternative Microbiological Sampling Methods for Nonsterile Inhaled and Nasal Products .............................. 416
(611) Alcohol Determination .......................................................... 418
(616) Bulk Density and Tapped Density of Powders ......................... 420
(621) Chromatography ................................................................ 424
(631) Color and Chromaticity .......................................................... 434
(641) Completeness of Solution ......................................................... 436
(643) Total Organic Carbon .............................................................. 436
(645) Water Conductivity ................................................................ 438
(651) Congealing Temperature ........................................................... 441
(659) Packaging and Storage Requirements ......................................... 443
(660) Containers—Glass ................................................................. 450
(661) Containers—Plastics ................................................................. 457
(670) Auxiliary Packaging Components .............................................. 463
(671) Containers—Performance Testing ............................................. 465
(693) Cotton ........................................................................... 472
(695) Crystallinity ...................................................................... 474
(696) Characterization of Crystalline Solids by Microcalorimetry and Solution Calorimetry ........................................... 474
(697) Container Content for Injections .............................................. 478
(698) Deliverable Volume ................................................................. 478
(699) Density of Solids .................................................................. 481
(701) Disintegration .................................................................... 483
(703) Quality as Having a Functional Score ........................................ 485
(711) Dissolution ....................................................................... 486
(721) Distilling Range .................................................................. 496
(724) Drug Release ..................................................................... 497
(729) Globule Size Distribution in Lipid Injectable Emulsions .......... 504
(730) Plasma Spectrochemistry .......................................................... 506
(731) Loss on Drying .................................................................. 513
(733) Loss on Ignition .................................................................. 514
(735) X-Ray Fluorescence Spectrometry ........................................... 514
(736) Mass Spectrometry ................................................................. 519
(741) Melting Range or Temperature ................................................ 525
(751) Metal Particles in Ophthalmic Ointments .................................. 527
(753) Minimum Fill ..................................................................... 527
(761) Nuclear Magnetic Resonance Spectroscopy ............................. 528
(771) Ophthalmic Ointments ............................................................ 537
(776) Optical Microscopy ................................................................ 537
(781) Optical Rotation .................................................................. 540
(785) Osmolality and Osmolarity ..................................................... 541
(786) Particle Size Distribution Estimation by Analytical Sieving ....... 543
(787) Subvisible Particulate Matter in Therapeutic Protein Injections .................................................. 547
(788) Particulate Matter in Injections ............................................... 550
(789) Particulate Matter in Ophthalmic Solutions ................................ 553
(790) Visible Particulates in Injections .............................................. 555
(791) pH ............................................................................... 556
(795) Pharmaceutical Compounding—Nonsterile Preparations ........ 559
(797) Pharmaceutical Compounding—Sterile Preparations ................ 567
(801) Polarographic Methods .......................................................... 611
(811) Powder Fineness ................................................................ 616
(821) Radioactivity ..................................................................... 616
(823) Positron Emission Tomography ............................................... 623

GENERAL INFORMATION

(1005) Acoustic Emission .............................................................. 699
(1010) Analytical Data—Interpretation and Treatment ....................... 703
(1015) Automated Radiochemical Synthesis Apparatus ................. 717
(1024) Bovine Serum .................................................................. 719
(1027) Flow Cytometry ................................................................. 732
(1030) Biological Assay Chapters—Overview and Glossary .............. 748
(1031) The Biocompatibility of Materials Used in Drug Containers, Medical Devices, and Implants .................................................. 759
(1032) Design and Development of Biological Assays ....................... 769
(1033) Biological Activity Validation ............................................... 787
(1034) Analysis of Biological Assays .............................................. 801
(1035) Biological Indicators for Sterilization .................................... 814
(1041) Biologics ........................................................................ 818
(1043) Ancillary Materials for Cell, Gene, and Tissue-Engineered Products .......................................................... 819
(1044) Cryopreservation of Cells ..................................................... 827
(1045) Biotechnology-Derived Articles ............................................. 840
| (1046) Cellular and Tissue-Based Products | 854 |
| (1047) Gene Therapy Products | 883 |
| (1048) Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products | 911 |
| (1049) Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products | 913 |
| (1050) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin | 918 |
| (1051) Cleaning Glass Apparatus | 931 |
| (1052) Biotechnology-Derived Articles—Amino Acid Analysis | 944 |
| (1053) Capillary Electrophoresis | 951 |
| (1054) Biotechnology-Derived Articles—Isoelectric Focusing | 954 |
| (1055) Biotechnology-Derived Articles—Peptide Mapping | 957 |
| (1056) Biotechnology-Derived Articles—Polyacrylamide Gel Electrophoresis | 960 |
| (1057) Biotechnology-Derived Articles—Total Protein Assay | 967 |
| (1058) Analytical Instrument Qualification | 971 |
| (1059) Excipient Performance | 977 |
| (1060) Color—Instrumental Measurement | 997 |
| (1061) Ion Chromatography | 1000 |
| (1062) Physical Environments That Promote Safe Medication Use | 1003 |
| (1063) Disinfectants and Antiseptics | 1010 |
| (1064) Excipient Biological Safety Evaluation Guidelines | 1015 |
| (1065) Good Manufacturing Practices for Bulk Pharmaceutical Excipients | 1019 |
| (1066) Good Storage and Distribution Practice for Drug Products | 1035 |
| (1067) Bulk Pharmaceutical Excipients—Certificate of Analysis | 1044 |
| (1068) Glycoprotein and Glycan Analysis—General Considerations | 1052 |
| (1069) Impurities in Drug Substances and Drug Products | 1063 |
| (1070) Apparent Intrinsic Dissolution—Dissolution Testing Procedures for Rotating Disk and Stationary Disk | 1066 |
| (1071) In Vitro and In Vivo Evaluation of Dosage Forms | 1070 |
| (1072) Assessment of Drug Product Performance—Bioavailability, Bioequivalence, and Dissolution | 1081 |
| (1073) Labeling of Inactive Ingredients | 1089 |
| (1074) The Dissolution Procedure: Development and Validation | 1090 |
| (1075) Capsules—Dissolution Testing and Related Quality Attributes | 1097 |
| (1076) Bulk Powder Sampling Procedures | 1105 |
| (1077) Immunological Test Methods—General Considerations | 1107 |
| (1078) Immunological Test Methods—Enzyme-Linked Immunosorbent Assay (ELISA) | 1125 |
| (1079) Immunological Test Methods—Immunoblot Analysis | 1135 |
| (1080) Immunological Test Methods—Surface Plasmon Resonance | 1146 |
| (1081) Immunogenicity Assays—Design and Validation of Immunoassays to Detect Anti-Drug Antibodies | 1161 |
| (1082) Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use | 1176 |
| (1083) Application of Water Activity Determination to Nonsterile Pharmaceutical Products | 1178 |
| (1113) Microbial Characterization, Identification, and Strain Typing | 1180 |
| (1114) Bioburden Control of Nonsterile Drug Substances and Products | 1185 |
| (1115) Microbiological Control and Monitoring of Aseptic Processing Environments | 1191 |
| (1116) Microbiological Best Laboratory Practices | 1204 |
| (1117) Monitoring Devices—Time, Temperature, and Humidity | 1210 |
| (1118) Near-Infrared Spectroscopy | 1215 |
| (1119) Raman Spectroscopy | 1222 |
| (1120) Nomenclature | 1230 |
| (1121) Nucleic Acid-Based Techniques—General | 1232 |
| (1122) Nucleic Acid-Based Techniques—Extraction, Detection, and Sequencing | 1237 |
| (1123) Nucleic Acid-Based Techniques—Amplification | 1247 |
| (1124) Nucleic Acid-Based Techniques—Microarraying | 1256 |
| (1125) Nucleic Acid-Based Techniques—Genotyping | 1262 |
| (1126) Nucleic Acid-Based Techniques—Approaches for Detecting Trace Nucleic Acids (Residual DNA Testing) | 1267 |
| (1127) Packaging and Repackaging—Single-Unit Containers | 1269 |
| (1128) Pharmaceutical Dosage Forms | 1278 |
| (1129) Animal Drugs for Use in Animal Feeds | 1301 |
| (1130) Pharmaceutical Calculations in Prescription Compounding | 1303 |
| (1131) Quality Assurance in Pharmaceutical Compounds | 1317 |
| (1132) Phase-Solubility Analysis | 1324 |
| (1133) Powder Flow | 1326 |
| (1134) Prescription Balances and Volumetric Apparatus | 1331 |
| (1135) Good Packaging Practices | 1335 |
| (1136) Human Plasma | 1337 |
| (1137) Scanning Electron Microscopy | 1360 |
| (1138) Sensitization Testing | 1370 |
| (1139) Stability Considerations in Dispensing Practice | 1381 |
| (1140) Significant Change Guide for Bulk Pharmaceutical Excipients | 1385 |
| (1141) Good Distribution Practices For Bulk Pharmaceutical Excipients | 1396 |
| (1142) Sterile Product Packaging—Integrity Evaluation | 1418 |
| (1143) Sterility Testing—Validation of Isolator Systems | 1420 |
| (1144) Sterilization—Chemical and Physicochemical Indicators and Integrators | 1424 |
| (1145) Sterilization and Sterility Assurance of Compendial Articles | 1427 |
| (1146) Tablet Friability | 1432 |
| (1147) Tablet Breaking Force | 1433 |
| (1148) Terminally Sterilized Pharmaceutical Products—Parametric Release | 1436 |
| (1149) Transfer of Analytical Procedures | 1439 |
| (1150) Validation of Alternative Microbiological Methods | 1443 |
| (1151) Validation of Compendial Procedures | 1445 |
| (1152) Verification of Compendial Procedures | 1451 |
| (1153) Validation of Microbial Recovery from Pharmacopeial Articles | 1452 |
| (1154) Sterilization of Compendial Articles | 1456 |
| (1155) Steam Sterilization by Direct Contact | 1461 |
| (1156) Moist Heat Sterilization of Aqueous Liquids | 1464 |
| (1157) Monitoring of Bioburden | 1468 |
| (1158) Sterilizing Filtration of Liquids | 1472 |
| (1159) Liquid-Phase Sterilization | 1479 |
| (1160) Gaseous Sterilization | 1482 |
| (1161) Dry Heat Sterilization | 1485 |
(1229.10) Radiation Sterilization ......................... 1487
(1230) Water for Hemodialysis Applications ............ 1491
(1231) Water for Pharmaceutical Purposes .............. 1492
(1234) Vaccines for Human Use—Polysaccharide and Glycoconjugate Vaccines ...................... 1518
(1235) Vaccines for Human Use—General Considerations .................................................. 1534
(1237) Virology Test Methods ............................................. 1550
(1238) Vaccines for Human Use—Bacterial Vaccines ..................................................................... 1570
(1240) Virus Testing of Human Plasma for Further Manufacture ........................................... 1582
(1241) Water–Solid Interactions in Pharmaceutical Systems ..................................................... 1592
(1251) Weighing on an Analytical Balance ...................... 1597
(1265) Written Prescription Drug Information—Guidelines .................................................... 1602
(1285) Preparation of Biological Specimens for Histologic and Immunohistochemical Analysis .......................................................................................................................... 1603
(1285.1) Hematoxylin and Eosin Staining of Sectioned Tissue for Microscopic Examination ............ 1607
(1604) Theory and Practice of Electrical Conductivity Measurements of Solutions ................ 1614
(1660) Evaluation of the Inner Surface Durability of Glass Containers .................................. 1620
(1724) Semisolid Drug Products—Performance Tests ......................................................................... 1625
(1736) Applications Of Nuclear Magnetic Resonance Spectroscopy ...................................... 1637
(1761) Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections .............. 1669

(1787) Methods for the Determination of Particulate Matter in Injections and Ophthalmic Solutions .................................................................................................................. 1693
(1852) Atomic Absorption Spectroscopy—Theory and Practice .................................................. 1706
(1853) Fluorescence Spectroscopy—Theory and Practice ............................................................. 1714
(1854) Mid-Infrared Spectroscopy—Theory and Practice ............................................................. 1724
(1857) Ultraviolet-Visible Spectroscopy—Theory and Practice ................................................... 1733
(1911) Rheometry ......................................................................................................................... 1742

DIETARY SUPPLEMENTS
(2021) Microbial Enumeration Tests—Nutritional and Dietary Supplements ............................. 1751
(2022) Microbiological Procedures for Absence of Specified Microorganisms—Nutritional and Dietary Supplements ................................................................. 1756
(2023) Microbiological Attributes of Nonsterile Nutritional and Dietary Supplements .............. 1762
(2030) Supplemental Information for Articles of Botanical Origin .............................................. 1765
(2040) Disintegration and Dissolution of Dietary Supplements ................................................. 1774
(2091) Weight Variation of Dietary Supplements ........................................................................... 1782
(2232) Elemental Contaminants in Dietary Supplements ............................................................ 1783
(2250) Detection of Irradiated Dietary Supplements .................................................................... 1786
(2750) Manufacturing Practices for Dietary Supplements ........................................................ 1789
General Notices and Requirements

Applying to Standards, Tests, Assays, and Other Specifications of the United States Pharmacopeia

1. Title and Revision ........................................... xiii

2. Official Status and Legal Recognition .................... xiii
   2.10. Official Text ........................................ xiii
   2.20. Official Articles .................................... xiii
   2.30. Legal Recognition .................................. xiii

3. Conformance to Standards ................................ xiii
   3.10. Applicability of Standards ....................... xiii
   3.20. Indicating Conformance ............................ xiv

4. Monographs and General Chapters ....................... xiv
   4.10. Monographs ......................................... xiv
   4.20. General Chapters .................................. xv

5. Monograph Components .................................... xv
   5.10. Molecular Formula ................................ xv
   5.20. Added Substances ................................. xv
   5.30. Description and Solubility ..................... xvi
   5.40. Identity ............................................ xvi
   5.50. Assay ................................................ xvi
   5.60. Impurities and Foreign Substances .......... xvi
   5.70. Performance Tests ............................... xvi
   5.80. USP Reference Standards ...................... xvii

   6.10. Safe Laboratory Practices .................... xvi
   6.20. Automated Procedures .......................... xvi
   6.30. Alternative and Harmonized Methods and Procedures .......... xvi
   6.40. Dried, Anhydrous, Ignited, or Solvent-Free Basis .......... xvi
   6.50. Preparation of Solutions ..................... xvii
   6.60. Units Necessary to Complete a Test .......... xviii
   6.70. Reagents ........................................... xviii
   6.80. Equipment ........................................ xviii

7. Test Results ............................................... xviii
   7.10. Interpretation of Requirements ............... xviii
   7.20. Rounding Rules .................................... xviii

8. Terms and Definitions .................................. xix
   8.10. Abbreviations .................................... xix
   8.20. About ................................................ xix
   8.30. Alcohol Content ................................ xix
   8.40. Atomic Weights ................................ xix
   8.50. Blank Determinations ............................ xix
   8.60. Concomitantly ................................... xix
   8.70. Desiccator .......................................... xix
   8.80. Logarithms ......................................... xix
   8.90. Microbial Strain ................................. xix
   8.100. Negligible ....................................... xix
   8.110. NLT/NMT .......................................... xix
   8.120. Odor ................................................ xix
   8.130. Percent ............................................ xix
   8.140. Percentage Concentrations ............... xix
   8.150. Pressure ........................................... xix
   8.160. Reaction Time ................................... xix
   8.170. Specific Gravity ................................. xix
   8.180. Temperatures .................................... xix
   8.190. Time ............................................... xx
   8.200. Transfer ........................................... xx
   8.220. Vacuum ............................................ xx
   8.230. Water ................................................ xx
   8.240. Weights and Measures ....................... xx
9. Prescribing and Dispensing .......................... xxi
9.10 Use of Metric Units ............................... xxi
9.20 Changes in Volume ............................... xxi

10. Preservation, Packaging, Storage, and Labeling .......................... xxi
10.10. Packaging and Storage ......................... xxi
10.40. Labeling ........................................ xxi
GENERAL NOTICES AND REQUIREMENTS

The General Notices and Requirements section (the General Notices) presents the basic assumptions, definitions, and default conditions for the interpretation and application of the United States Pharmacopeia (USP) and the National Formulary (NF).

Requirements stated in these General Notices apply to all articles recognized in the USP and NF (the “compendia”) and to all general chapters unless specifically stated otherwise. Where the requirements of an individual monograph differ from the General Notices or a general chapter, the monograph requirements apply and supersede the requirements of the General Notices or the general chapter, whether or not the monograph explicitly states the difference.

1. TITLE AND REVISION

The full title of this publication (consisting of four volumes and including its Supplements), is The Pharmacopeia of the United States of America, Thirty-Eighth Revision and the National Formulary, Thirty-Third Edition. These titles may be abbreviated to USP 38, to NF 33, and to USP 38–NF 33. The United States Pharmacopeia, Thirty-Eighth Revision, and the National Formulary, Thirty-Third Edition, supersede all earlier revisions. Where the terms “USP,” “NF,” or “USP-NF” are used without further qualification during the period in which these compendia are official, they refer only to USP 38, NF 33, and any Supplement(s) thereto. The same titles, with no further distinction, apply equally to print or electronic presentation of these contents. Although USP and NF are published under one cover and share these General Notices, they are separate compendia.

This revision is official beginning May 1, 2015, unless otherwise indicated in specific text.

Supplements to USP and NF are published periodically.

Interim Revision Announcements are revisions to USP and NF that are published on the USP website. Interim Revision Announcements contain official revisions and their effective dates. Announcements of the availability of new USP Reference Standards and announcements of tests or procedures that are held in abeyance pending availability of required USP Reference Standards are also available on the “New Official Text” tab of USP’s website.

Revision Bulletins are revisions to official text or postpositions that require expedited publication. They are published on the USP website and generally are official immediately unless otherwise specified in the Revision Bulletin.

Errata are corrections to items erroneously published that have not received the approval of the Council of Experts and that do not reflect the official requirements.

2. OFFICIAL STATUS AND LEGAL RECOGNITION

2.10. Official Text

Official text is text contained in USP and NF, including monographs, general chapters, and these General Notices. Revisions to official text are provided in Supplements, Interim Revision Announcements, and Revision Bulletins. General chapters numbered from 1000 to 1999 are considered interpretive and are intended to provide information on, give definition to, or describe a particular subject. They contain no mandatory requirements applicable to any official article unless specifically referenced in General Notices, a monograph, or a general chapter numbered below 1000. General chapters numbered above 2000 apply only to articles that are intended for use as dietary ingredients and dietary supplements.

2.20. Official Articles

An official article is an article that is recognized in USP or NF. An article is deemed to be recognized and included in a compendium when a monograph for the article is published in the compendium and an official date is generally or specifically assigned to the monograph.

The title specified in a monograph is the official title for such article. Other names considered to be synonyms of the official titles may not be used as substitutes for official titles. Official articles include both official substances and official products. An official substance is a drug substance, excipient, dispersion ingredient, other ingredient, or component of a finished device for which the monograph title includes no indication of the nature of the finished form.

An official product is a drug product, dietary supplement, compounded preparation, or finished device for which a monograph is provided.

2.30. Legal Recognition

The USP and NF are recognized in the laws and regulations of many countries throughout the world. Regulatory authorities may enforce the standards published in the USP and NF, but because recognition of the USP and NF may vary by country, users should understand applicable laws and regulations. In the United States under the Federal Food, Drug, and Cosmetic Act (FDCA), both USP and NF are recognized as official compendia. A drug with a name recognized in USP–NF must comply with compendial identity standards or be deemed adulterated, misbranded, or both. See, e.g., FDCA § 501(b) and 502(e)(3)(b); also FDA regulations, 21 CFR § 299.5(a&b). To avoid being deemed adulterated, such drugs must also comply with compendial standards for strength, quality, and purity, unless labeled to show all respects in which the drug differs. See, e.g., FDCA § 501(b) and 21 CFR § 299.5(c). In addition, to avoid being deemed misbranded, drugs recognized in USP–NF must also be packaged and labeled in compliance with compendial standards. See FDCA § 502(g).

A dietary supplement represented as conforming to specifications in USP will be deemed a misbranded food if it fails to so conform. See FDCA § 403(s)(2)(D).

Enforcement of USP standards is the responsibility of FDA and other government authorities in the U.S. and elsewhere. USP has no role in enforcement.

3. CONFORMANCE TO STANDARDS

3.10. Applicability of Standards

Standards for an article recognized in the compendia (USP–NF) are expressed in the article’s monograph, applicable general chapters, and General Notices. Unless specifically exempted elsewhere in a compendium, the identity, strength, quality, and purity of an article are determined by the official tests, procedures, and acceptance criteria, whether incorporated in the monograph itself, in the General Notices, or in the applicable general chapters. Early adoption of revised standards is allowed. Where revised standards for an existing article have been published as final and approved “official text” (as approved in section 2.10) but are not yet official (six months after publication, unless otherwise specified; see “official date,” section 2.20), compliance with the revised standard shall not preclude a finding or indication of conformance with compendial standards.
unless USP specifies otherwise by prohibiting early adoption in a particular standard.

The standards in the relevant monograph, general chapter(s), and General Notices apply at all times in the life of the article from production to expiration. The manufacturer’s specifications, and good manufacturing practices generally (including, e.g., Quality by Design initiatives), are developed and followed to ensure that the article will comply with compendial standards until its expiration date, when stored as directed. Thus, any official article is expected to meet the compendial standards if tested, and any official article actually tested as directed in the relevant monograph must meet such standards to demonstrate compliance.

At times, compendial standards take on the character of statistical procedures, with multiple units involved and perhaps a sequential procedural design to allow the user to determine that the tested article meets or does not meet the standard. The similarity to statistical procedures may seem to suggest an intent to make inference to some larger group of units, but in all cases, statements about whether the compendial standard is met apply only to the units tested. Repeats, replicates, statistical rejection of outliers, or extrapolations of results to larger populations, as well as the need for and application of batch testing are neither specified nor proscribed by the compendia. Frequency of testing and sampling are left to the preferences or direction of those performing compliance testing, and other users of USP-NF, including manufacturers, buyers, or regulatory authorities.

Official products are prepared according to recognized principles of good manufacturing practice and from ingredients that meet USP or NF standards, where standards for such ingredients exist (for dietary supplements, see section 3.10.20).

Official substances are prepared according to recognized principles of good manufacturing practice and from ingredients complying with specifications designed to ensure that the resultant substances meet the requirements of the compendial monographs.

### 3.10.10. Applicability of Standards to Drug Products, Drug Substances, and Excipients

The applicable USP or NF standard applies to any article marketed in the United States that (1) is recognized in the compendium and (2) is intended or labeled for use as a drug or an ingredient in a drug. Such articles (drug products, drug substances, and excipients) include both human drugs (whether dispensed by prescription, “over the counter,” or otherwise), as well as animal drugs. The applicable standard applies to such articles whether or not the added designation “USP” or “NF” is used. The standards apply equally to articles bearing the official titles or names derived by transposition of the definitive words of official titles or transposition in the order of the names of two or more active ingredients in official titles, or where there is use of synonyms with the intent or effect of suggesting a significant degree of identity with the official title or name.

### 3.10.20. Applicability of Standards to Medical Devices, Dietary Supplements, and Their Components and Ingredients

An article recognized in USP or NF shall comply with the compendial standards if the article is a medical device, component intended for a medical device, dietary supplement, dietary ingredient, or other ingredient that is intended for incorporation into a dietary supplement, and is labeled as containing to be administered in USP or NF.

Generally, dietary supplements are prepared from ingredients that meet USP, NF, or Food Chemicals Codex standards. Where such standards do not exist, substances may be used in dietary supplements if they have been shown to be of acceptable food grade quality using other suitable procedures.

### 3.20. Indicating Conformance

A drug product, drug substance, or excipient may use the designation “USP” or “NF” in conjunction with its official title or elsewhere on the label only when (1) a monograph is provided in the specified compendium and (2) the article complies with the identity prescribed in the specified compendium.

When a drug product, drug substance, or excipient differs from the relevant USP or NF standard of strength, quality, or purity, as determined by the application of the tests, procedures, and acceptance criteria set forth in the relevant compendium, its difference shall be plainly stated on its label.

When a drug product, drug substance, or excipient fails to comply with the identity prescribed in USP or NF and contains an added substance that interferes with the prescribed tests and procedures, the article shall be designated by a name that is clearly distinguishing and differentiating from any name recognized in USP or NF.

A medical device, dietary supplement, or ingredient or component of a medical device or dietary supplement may use the designation “USP” or “NF” in conjunction with its official title or elsewhere on the label only when (1) a monograph is provided in the specified compendium and (2) the article complies with the monograph standards and other applicable standards in the compendium.

The designation “NF” on a label may not and does not constitute an endorsement by USP and does not represent assurance by USP that the article is known to comply with the relevant standards. USP may seek legal redress if an article purports to be or is represented as an official article in one of USP’s compendia and such claim is determined by USP not to be made in good faith.

The designation “USP-NF” may be used on the label of an article provided such label also bears a statement such as “Meets NF standards as published by USP,” indicating the particular compendium to which the article purports to apply.

When the letters “USP,” “NF,” or “USP-NF” are used on the label of an article to indicate compliance with compendial standards, the letters shall appear in conjunction with the official title of the article. The letters are not to be enclosed in any symbol, such as a circle, square, etc., and shall appear in capital letters.

If a dietary supplement does not comply with all applicable compendial requirements but contains one or more dietary ingredients or other ingredients that are recognized in USP or NF, the individual ingredient(s) may be designated as complying with USP or NF standards or being of USP or NF quality provided that the designation is limited to the individual ingredient(s) and does not suggest that the dietary supplement complies with USP standards.

### 4. MONOGRAPHS AND GENERAL CHAPTERS

#### 4.10. Monographs

Monographs set forth the article’s name, definition, specification, and other requirements related to packaging, storage, and labeling. The specification consists of tests, procedures, and acceptance criteria that help ensure the identity, strength, quality, and purity of the article. For general requirements relating to specific monograph sections, see section 5, Monograph Components.

Because monographs may not provide standards for all relevant characteristics, some official substances may conform to the USP or NF standard but differ with regard to nonstandardized properties that are relevant to their use in specific preparations. To assure interchangeability in such instances, users may wish to ascertain functional equivalence or determine such characteristics before use.

#### 4.10.10. Applicability of Test Procedures

A single monograph may include several different tests, procedures, and/or acceptance criteria that reflect attributes of different manufacturers’ articles. Such alternatives may be presented for different polymorphic forms, impurities, hydrates, and dissolution cases. Monographs indicate the tests, procedures, and/or acceptance criteria to be used and the required labeling.

A test in a monograph may contain and require multiple procedures. However, multiple procedures may be included
in particular monographs specifically for the purpose of assuring the availability of an appropriate procedure for a particular product. In such cases, a labeling statement to indicate the appropriate application of the procedure(s) will be included in the monograph. A labeling statement is not required if Test 1 is used.

4.10.11. Dissolution, Disintegration, and Drug Release Tests

Multiple Dissolution, Disintegration, or Drug Release tests may be present in the monograph. The order in which the tests are listed in the monograph is based on the order in which they are approved by the relevant Expert Committee for inclusion in the monograph. Test 1 is not necessarily the test for the innovator or for the reference product. Compliance with any of the tests does not assure bioequivalence or bioavailability.

4.10.20. Acceptance Criteria

The acceptance criteria allow for analytical error, for unavoidable variations in manufacturing and compounding, and for deterioration to an extent considered acceptable under practical conditions. The existence of compendial acceptance criteria does not constitute a basis for a claim that an official article is intended to have characteristics that exceed those specified in the monograph; the compendial requirements do not constitute a basis for a claim that the article “exceeds” the compendial quality. Similarly, the fact that an article has been prepared to tighter criteria than those specified in the monograph does not constitute a basis for a claim that the article “exceeds” the compendial requirements.

An official product shall be formulated with the intent to provide 100 percent of the quantity of each ingredient declared on the label. Where the minimum amount of a substance present in a dietary supplement is required by law to be greater than the lower acceptance criterion allowed for in the monograph, the upper acceptance criterion contained in the monograph may be increased by a corresponding amount.

The acceptance criteria specified in individual monographs and in the general chapters for compounded preparations are based on such attributes of quality as might be expected to characterize an article compounded from suitable bulk drug substances and ingredients, using the procedures provided or recognized principles of good compounding practice, as described in these compendia.

4.20. General Chapters

Each general chapter is assigned a number that appears in angle brackets adjacent to the chapter name (e.g., Chromatography (621)). General chapters may contain the following:

- Descriptions of tests and procedures for application through individual monographs
- Descriptions and specifications of conditions and practices for pharmaceutical compounding
- General information for the interpretation of the compendial requirements
- Descriptions of general pharmaceutical storage, dispensing, and packaging practices
- General guidance to manufacturers of official substances or official products

When a general chapter is referenced in a monograph, acceptance criteria may be presented after a colon.

Some chapters may serve as introductory overviews of a test or of analytical techniques. They may reference other general chapters that contain techniques, details of the procedures, and, at times, acceptance criteria.

5. MONOGRAPH COMPONENTS

5.10. Molecular Formula

The use of the molecular formula for the active ingredient(s) named in defining the required strength of a compendial article is intended to designate the chemical entity or entities, as given in the complete chemical name of the article, having absolute (100 percent) purity.

5.20. Added Substances

Added substances are presumed to be unsuitable for inclusion in an official article and therefore prohibited, if: (1) they exceed the minimum quantity required for providing their intended effect; (2) their presence impairs the bioavailability, therapeutic efficacy, or safety of the official article; or (3) they interfere with the assays and tests prescribed for determining compliance with the compendial standards.

The air in a container of an official article may, where appropriate, be evacuated or be replaced by carbon dioxide, helium, argon, or nitrogen, or by a mixture of these gases. The use of such gas need not be declared in the labeling.

5.20.10. Added Substances, Excipients, and Ingredients in Official Substances

Official substances may contain only the specific added substances that are permitted by the individual monograph. Where such addition is permitted, the label shall indicate the name(s) and amount(s) of any added substance(s).

5.20.20. Added Substances, Excipients, and Ingredients in Official Products

Suitable substances and excipients such as antimicrobial agents, pharmaceutical bases, carriers, coatings, flavors, preservatives, stabilizers, and vehicles may be added to an official product to enhance its stability, usefulness, or elegance, or to facilitate its preparation, unless otherwise specified in the individual monograph.

Added substances and excipients employed solely to impart color may be incorporated into official products other than those intended for parenteral or ophthalmic use, in accordance with the regulations pertaining to the use of colors issued by the U.S. Food and Drug Administration (FDA), provided such added substances or excipients are otherwise appropriate in all respects. (See also Added Substances under Injections (1)).

The proportions of the substances constituting the base in ointment and suppository products and preparations may be varied to maintain a suitable consistency under different climatic conditions, provided that the concentrations of active ingredients are not varied and provided that the bioavailability, therapeutic efficacy, and safety of the preparation are not impaired.

5.20.20.1. In Compounded Preparations

Compounded preparations for which a complete composition is given shall contain only the ingredients named in the formulas unless specifically exempted herein or in the individual monograph. Deviation from the specified processes or methods of compounding, although not from the ingredients or proportions thereof, may occur provided that the finished preparation conforms to the relevant standards and to preparations produced by following the specified process.

Where a monograph for a compounded preparation calls for an ingredient in an amount expressed on the dried basis, the ingredient need not be dried before use if due allowance is made for the water or other volatile substances present in the quantity taken.

Specially denatured alcohol formulas are available for use in accordance with federal statutes and regulations of the Internal Revenue Service. A suitable formula of specially denatured alcohol may be substituted for Alcohol in the manufacture of official preparations intended for internal or topical use, provided that the denaturant is volatile and does not remain in the finished product. A preparation that is intended for topical application to the skin may contain specially denatured alcohol, provided that the denaturant is either a usual ingredient in the preparation or a permissible added substance; in either case the denaturant shall be identified on the label of the topical preparation. Where a process is given in the individual monograph, any preparation compounded using denatured alcohol shall be identical to that prepared by the monograph process.
5.20.20.2 In Dietary Supplements

Additional ingredients may be added to dietary supplement products provided that the additional ingredients: (1) comply with applicable regulatory requirements; and (2) do not interfere with the assays and tests prescribed for determining compliance with compendial standards.

5.30. Description and Solubility

Only where a quantitative solubility test is given in a monograph and is designated as such is it a test for purity. A monograph may include information regarding the article’s description. Information about an article’s “description and solubility” also is provided in the reference table Description and Relative Solubility of USP and NF Articles. The reference table merely denotes the properties of articles that comply with monograph standards. The reference table is intended primarily for those who use, prepare, and dispense drugs and/or related articles. Although the information provided in monographs and the information in the reference table may indirectly assist in the preliminary evaluation of an article, it is not intended to serve as a standard or test for purity.

5.40. Identity

A compendial test titled Identity or Identification is provided as an aid in verifying the identity of articles as they are purported to be, e.g., those taken from labeled containers, and to establish whether it is the article named in USP–NF. The Identity or Identification test for a particular article may consist of one or more procedures. When a compendial test for Identity or Identification is undertaken, all requirements of all specified procedures in the test must be met to satisfy the requirements of the test. Failure of an article to meet all the requirements of a prescribed Identity or Identification test (i.e., failure to meet the requirements of all of the specified procedures that are components of that test) indicates that the article is mislabeled and/or adulterated.

5.50. Assay

Assay tests for compounded preparations are not intended for evaluating a compounded preparation before dispensing, but instead are intended to serve as the official test in the event of a question or dispute regarding the preparation’s conformance to official standards.

5.60. Impurities and Foreign Substances

Tests for the presence of impurities and foreign substances are provided to limit such substances to amounts that are unobjectionable under conditions in which the article is customarily employed (see also Impurities in Drug Substances and Drug Products (1086)).

Nonmonograph tests and acceptance criteria suitable for detecting and controlling impurities that may result from a change in the processing methods or that may be introduced from external sources should be employed in addition to the tests provided in the individual monograph, where the presence of the impurity is inconsistent with applicable good manufacturing practices or good pharmaceutical practice.

5.60.10. Other Impurities in USP and NF Articles

If a USP or NF monograph includes an assay or organic impurity test based on chromatography, other than a test for residual solvents, and that monograph procedure does not detect an impurity present in the substance, the amount and identity of the impurity, where both are known, shall be stated in the labeling (certificate of analysis) of the official substance, under the heading Other Impurity(ies). The presence of any unlabeled other impurity in an official substance is a variance from the standard if the content is 0.1% or greater. The sum of all other Impurities combined with the monograph-detected impurities may not exceed 2.0% (see Ordinary Impurities (466)), unless otherwise stated in the monograph.

The following categories of drug substances are excluded from Other Impurities requirements:
- Fermentation products and semi-synthetics derived therefrom,
- Radiopharmaceuticals,
- Biologics,
- Biotechnology-derived products,
- Peptides,
- Herbals, and
- Crude products of animal or plant origin.

Any substance known to be toxic shall not be listed under Other Impurities.

5.60.20. Residual Solvents in USP and NF Articles

All USP and NF articles are subject to relevant control of residual solvents, even when no test is specified in the individual monograph. If solvents are used during production, they must be of suitable quality. In addition, the toxicity and residual level of each solvent shall be taken into consideration, and the solvents limited according to the principles defined and the requirements specified in Residual Solvents (467), using the general methods presented therein or other suitable methods.

5.60.30 Elemental Impurities in USP Drug Products and Dietary Supplements

[NOTE—General chapter (232) was published June 1, 2012, in the Second Supplement to USP 35–NF 30 and became official on February 1, 2013. General chapter (2232) was published February 1, 2013, in the First Supplement to USP 36–NF 31 and became official on August 1, 2013. The date of their applicability to articles recognized in USP–NF, however, is December 1, 2013, the date on which this General Notices provision becomes official.]

Elemental impurities are controlled in official drug products according to the principles defined and requirements specified in Elemental Impurities—Limits (232). Also see (232) for information related to drug substances and excipients. Elemental contaminants are controlled in official dietary supplements according to the principles defined and requirements specified in Elemental Contaminants in Dietary Supplements (2232).

(Official December 1, 2015)

5.70. Performance Tests

Where content uniformity determinations have been made using the same analytical methodology specified in the Assay, with appropriate allowances made for differences in sample preparation, the average of all of the individual

### Table: Description and Relative Solubility of USP and NF Articles

<table>
<thead>
<tr>
<th>Descriptive Term</th>
<th>Parts of Solvent Required for 1 Part of Solute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very soluble</td>
<td>Less than 1</td>
</tr>
<tr>
<td>Freely soluble</td>
<td>From 1 to 10</td>
</tr>
<tr>
<td>Soluble</td>
<td>From 10 to 30</td>
</tr>
<tr>
<td>Sparingly soluble</td>
<td>From 30 to 100</td>
</tr>
<tr>
<td>Slightly soluble</td>
<td>From 100 to 1,000</td>
</tr>
<tr>
<td>Very slightly soluble</td>
<td>From 1,000 to 10,000</td>
</tr>
<tr>
<td>Practically insoluble, or</td>
<td>Greater than or equal to 10,000</td>
</tr>
<tr>
<td>Insoluble</td>
<td></td>
</tr>
</tbody>
</table>
content uniformity determinations may be used as the Assay value.

5.80. USP Reference Standards

USP Reference Standards are authentic specimens that have been approved as suitable for use as comparison standards in USP or NF tests and assays. (See USP Reference Standards (11).) Where USP or NF tests or assays call for the use of a USP Reference Standard, only those results obtained using the specified USP Reference Standard are conclusive. Where a procedure calls for the use of a compendial article rather than for a USP Reference Standard as a material standard of reference, a substance meeting all of the compendial monograph requirements for that article shall be used. If any new USP or NF standard requires the use of a new USP Reference Standard that is not yet available, that portion of the standard containing the requirement shall not be official until the specified USP reference material is available.

Unless a reference standard label bears a specific potency or content, assume the reference standard is 100.0% pure in the official application. Unless otherwise directed in the procedure in the individual monograph or in a general chapter, USP Reference Standards are to be used in accordance with the instructions on the label of the Reference Standard.

Change to read:

6. TESTING PRACTICES AND PROCEDURES

6.10. Safe Laboratory Practices

In performing compendial procedures, safe laboratory practices shall be followed, including precautionary measures, protective equipment, and work practices consistent with the chemicals and procedures used. Before undertaking any procedure described in the compendia, the analyst should be aware of the hazards associated with the chemicals and the techniques and means of protecting against them. These compendia are not designed to describe such hazards or protective measures.

6.20. Automated Procedures

Automated and manual procedures employing the same basic chemistry are considered equivalent.

6.30. Alternative and Harmonized Methods and Procedures

Alternative methods and/or procedures may be used if they provide advantages in terms of accuracy, sensitivity, precision, selectivity, or adaptability to automation or computerized data reduction, or in other special circumstances. Such alternative procedures and methods shall be validated as described in the general chapter Validation of Compendial Procedures (1225) and must be shown to give equivalent or better results. Only those results obtained by the methods and procedures given in the compendium are conclusive. Alternative procedures should be submitted to USP for evaluation as a potential replacement or addition to the standard (see section 4.10, Monographs).

Certain general chapters contain a statement that the text in question is harmonized with the corresponding text of the European Pharmacopoeia and/or the Japanese Pharmacopoeia and that these texts are interchangeable. Therefore, if a substance or preparation is found to comply with a requirement using an interchangeable method or procedure from one of these pharmacopeias, it should comply with the requirements of the USP Standard. When a difference appears, or in the event of dispute, only the result obtained by the method and/or procedure given in the USP is conclusive.

6.40. Dried, Anhydrous, Ignited, or Solvent-Free Basis

All calculations in the compendia assume an “as-is” basis unless otherwise specified.

Test procedures may be performed on the undried or unignited substance and the results calculated on the dried, anhydrous, or ignited basis, provided a test for Loss on Drying, or Water Determination, or Loss on Ignition, respectively, is given in the monograph. Where the presence of moisture or other volatile material may interfere with the procedure, previous drying of the substance is specified in the individual monograph and is obligatory.

The term “solvent-free” signifies that the calculation shall be corrected for the presence of known solvents as determined using the methods described in Residual Solvents (467) unless a test for limit of organic solvents is provided in the monograph.

The term “previously dried” without qualification signifies that the substance shall be dried as directed under Loss on Drying (731) or Water Determination (921) (gravimetric determination).

When drying in vacuum over a desiccant is directed, a vacuum desiccator, a vacuum drying pistol, or other suitable vacuum drying apparatus shall be used.

6.40.10. Ignite to Constant Weight

“Ignite to constant weight” means that ignition shall be continued at 800 ± 25°, unless otherwise indicated, until two consecutive weighings, the second of which is taken after an additional period appropriate to the nature and quantity of the residue, do not differ by more than 0.50 mg per g of substance taken.

6.40.20. Dried to Constant Weight

“Dried to constant weight” means that drying shall be continued until two consecutive weighings, the second of which is taken after an additional drying period appropriate to the nature and quantity of the residue, do not differ by more than 0.50 mg per g of substance taken.

6.50. Preparation of Solutions

6.50.10. Filtration

Where a procedure gives direction to “filter” without further qualification, the liquid shall be passed through suitable filter paper or equivalent device until the filtrate is clear. Due to the possibility of filter effects, the initial volumes of a filtrate may be discarded.

6.50.20. Solutions

Unless otherwise specified, all solutions shall be prepared with Purified Water. Solutions for quantitative measures shall be prepared using accurately weighed or accurately measured analytes (see section 8.20, About).

An expression such as “(1 in 10)” means that 1 part by volume of a liquid shall be diluted with, “or 1 part by weight of a solid shall be dissolved in, a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts by volume.” An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated liquids shall be mixed, unless otherwise indicated.

6.50.20.1. Adjustments to Solutions

When a specified concentration is called for in a procedure, a solution of other normality or molarity may be used, provided that allowance is made for the difference in concentration and that the change does not increase the error of measurement.

Proportionately larger or smaller quantities than the specified weights and volumes of assay or test substances and Reference Standards may be taken, provided the measurement is made with at least equivalent accuracy.

Unless otherwise indicated, analyte concentrations shall be prepared to within ten percent (±10%) of the indicated value. In the special case in which a procedure is adapted to the working range of an instrument, solution concentrations may differ from the indicated value by more than ten percent (10%), with appropriate changes in associated calculations. Any changes shall fall within the validated range of the instrument.

When adjustment of pH is indicated with either an acid or base and the concentration is not indicated, appropriate concentrations of that acid or base may be used.

6.50.20.2. Test Solutions

Information on Test Solutions (TS) is provided in the Test Solutions portion of the Reagents, Indicators, and Solutions
section of the USP-NF. Use of an alternative Test Solution or a change in the Test Solution used may require validation.

6.50.20.3. Indicator Solutions
Where a procedure specifies the use of an indicator TS, approximately 0.2 mL, or 3 drops, of the solution shall be added unless otherwise directed.

6.60. Units Necessary to Complete a Test
Unless otherwise specified, a sufficient number of units to ensure a suitable analytical result shall be taken.

6.60.10. Tablets
Where the procedure of a Tablet monograph directs to weigh and finely powder not fewer than a given number of Tablets, a counted number of Tablets shall be weighed and reduced to a powder. The portion of the powdered Tablets taken shall be representative of the whole Tablets and shall, in turn, be weighed accurately.

6.60.20. Capsules
Where the procedure of a Capsule monograph gives direction to remove, as completely as possible, the contents of not fewer than a given number of the Capsules, a counted number of Capsules shall be carefully opened and the contents quantitatively removed, combined, mixed, and weighed accurately. The portion of mixed Capsules contents taken shall be representative of the contents of the Capsules and shall, in turn, be weighed accurately.

6.70. Reagents
The proper conduct of the compendial procedures and the reliability of the results depend, in part, upon the quality of the reagents used in the performance of the procedures. Unless otherwise specified, reagents conforming to the specifications set forth in the current edition of Reagent Chemicals published by the American Chemical Society (ACS) shall be used. Where such ACS reagent specifications are not available or where the required purity differs, compendial specifications for reagents of acceptable quality are provided (see the Reagents, Indicators, and Solutions section of the USP-NF). Reagents not covered by any of these specifications should be of a grade suitable to the proper performance of the method of assay or test involved.

Listing of these reagents, including the indicators and solutions employed as reagents, in no way implies that they have therapeutic utility; furthermore, any reference to USP or NF in their labeling shall include also the term “reagent” or “reagent grade.” USP may supply reagents if they otherwise may not be generally commercially available.

6.80. Equipment
Unless otherwise specified, a specification for a definite size or type of container or apparatus in a procedure is given solely as a recommendation. Other dimensions or types may be used if they are suitable for the intended use.

6.80.10. Apparatus for Measurement
Where volumetric flasks or other exact measuring, weighing, or sorting devices are specified, this or other equipment of at least equivalent accuracy shall be employed.

6.80.10.1. Pipet/Pipette
Where a pipet/pipette is specified, a suitable buret may be substituted. Where a “to contain” pipet/pipette is specified, a suitable volumetric flask may be substituted.

6.80.10.2. Light Protection
Where low-actinic or light-resistant containers are specified, either containers specially treated to protect contents from light or clear containers that have been rendered opaque by application of a suitable coating or wrapping may be used.

6.80.20. Instrumental Apparatus
An instrument may be substituted for the specified instrument if the substitute uses the same fundamental principles of operation and is of equivalent or greater sensitivity and accuracy. These characteristics shall be qualified as appropriate. Where a particular brand or source of a material, instrument, or piece of equipment, or the name and address of a manufacturer or distributor, is mentioned (ordinarily in a footnote), this identification is furnished solely for informational purposes as a matter of convenience, without implication of approval, endorsement, or certification.

6.80.20.3. Steam Bath
Where use of a steam bath is directed, use actively flowing steam or another regulated heat source controlled at an equivalent temperature.

6.80.20.4. Water Bath
A water bath requires vigorously boiling water unless otherwise specified.

6.80.30. Temperature Reading Devices
Temperature reading devices suitable for Pharmacopeial tests conform to specifications that are traceable to an NIST standard or equivalent. Temperature reading devices may be of the liquid-in-glass type or an analog or digital temperature indicator type, such as a resistance temperature device, thermometer, or thermocouple. Standardization of thermometers is performed on an established testing frequency with a temperature standard traceable to NIST. For example, refer to the current issue of ASTM standards E1 for liquid-in-glass thermometers.

7. TEST RESULTS

7.10. Interpretation of Requirements
Analytical results observed in the laboratory (or calculated from experimental measurements) are compared with stated acceptance criteria to determine whether the article conforms to compendial requirements.

The reportable value, which often is a summary value for several individual determinations, is compared with the acceptance criteria. The reportable value is the end result of a completed measurement procedure, as documented. Where acceptance criteria are expressed numerically herein through specification of an upper and/or lower limit, permitted values include the specified values themselves, but no values outside the limit(s). Acceptance criteria are considered significant to the last digit shown.

7.10.5. Nominal Concentrations in Equations
Where a “nominal concentration” is specified, calculate the concentration based on the label claim. In assay procedures, water correction is typically stated in the Definition and on the label of the USP Reference Standard. For other procedures, correction for assayed content, potency, or both is made prior to using the concentration in the equation provided in the monograph.

7.10.10. Equivalence Statements in Titrimetric Procedures
The directions for titrimetric procedures conclude with a statement of the weight of the analyte that is equivalent to each mL of the standardized titrant. In such an equivalence statement, the number of significant figures in the concentration of the titrant should be understood to correspond to the number of significant figures in the weight of the analyte. Corrections to calculations based on the blank determination are to be made for all titrimetric assays where appropriate (see Titrimetry (541)).

7.20. Rounding Rules
The observed or calculated values shall be rounded off to the number of decimal places that is in agreement with the limit expression. Numbers should not be rounded until the final calculations for the reportable value have been completed. Intermediate calculations (e.g., slope for linearity) may be rounded for reporting purposes, but the original (not rounded) value should be used for any additional required calculations. Acceptance criteria are fixed numbers and are not rounded.

When rounding is required, consider only one digit in the decimal place to the right of the last place in the limit expression. If this digit is smaller than 5, it is eliminated and
the preceding digit is unchanged. If this digit is equal to or greater than 5, it is eliminated and the preceding digit is increased by 1.

8. TERMS AND DEFINITIONS

8.10. Abbreviations

- RS refers to a USP Reference Standard.
- CS refers to a Colorimetric Solution.
- TS refers to a Test Solution.
- VS refers to a Volumetric Solution that is standardized in accordance with directions given in the individual monograph or in the Reagents, Indicators, and Solutions section of USP–NF.

8.20. About

"About" indicates a quantity within 10%.

If the measurement is stated to be "accurately measured" or "accurately weighed," follow the statements in the general chapters Volumetric Apparatus (31) and Balances (41), respectively.

8.30. Alcohol Content

Percentages of alcohol, such as those under the heading Alcohol Content, refer to percentage by volume of C₂H₅OH at 15.56°C. Where a formula, test, or assay calls for alcohol, ethyl alcohol, or ethanol, the USP monograph article Alcohol shall be used. Where reference is made to "C₂H₅OH," absolute (100 percent) ethanol is intended. Where a procedure calls for dehydrated alcohol, alcohol absolute, or anhydrous alcohol, the USP monograph article Dehydrated Alcohol shall be used.

8.40. Atomic Weights

Atomic weights used in computing molecular weights and the factors in the assays and elsewhere are those established by the IUPAC Commission on Atomic Weights and Isotopic Abundances.

8.50. Blank Determinations

Where it is directed that "any necessary correction" be made by a blank determination, the determination shall be conducted using the same quantities of the same reagents treated in the same manner as the solution or mixture containing the portion of the substance under assay or test, but with the substance itself omitted.

8.60. Concomitantly

"Concomitantly" denotes that the determinations or measurements are to be performed in immediate succession.

8.70. Desiccator

The instruction "in a desiccator" indicates use of a tightly closed container of suitable size and design that maintains an atmosphere of low moisture content by means of a suitable desiccant such as anhydrous calcium chloride, magnesium perchlorate, phosphorus pentoxide, or silica gel. See also section 8.220, Vacuum Desiccator.

8.80. Logarithms

Logarithms are to the base 10.

8.90. Microbial Strain

A microbial strain cited and identified by its ATCC catalog number shall be used directly or, if subcultured, shall be used not more than five passages removed from the original strain.

8.100. Negligible

"Negligible" indicates a quantity not exceeding 0.50 mg.

8.110. NLT/NMT

"NLT" means "not less than." "NMT" means "not more than."

8.120. Odor

"Odorless," "practically odorless," "a faint characteristic odor," and variations thereof indicate evaluation of a suitable quantity of freshly opened material after exposure to the air for 15 minutes. An odor designation is descriptive only and should not be regarded as a standard of purity for a particular lot of an article.

8.130. Percent

"Percent" used without qualification means:
- For mixtures of solids and semisolids, percent weight in weight;
- For solutions or suspensions of solids in liquids, percent weight in volume;
- For solutions of liquids in liquids, percent volume in volume;
- For solutions of gases in liquids, percent weight in volume.

For example, a 1 percent solution is prepared by dissolving 1 g of a solid or semisolid, or 1 mL of a liquid, in sufficient solvent to make 100 mL of the solution.

8.140. Percentage Concentrations

Percentage concentrations are expressed as follows:
- Percent Weight in Weight (w/w) is defined as the number of g of a solute in 100 g of solution.
- Percent Weight in Volume (w/v) is defined as number of g of a solute in 100 mL of solution.
- Percent Volume in Volume (v/v) is defined as the number of mL of a solute in 100 mL of solution.

8.150. Pressure

Pressure is determined by use of a suitable manometer or barometer calibrated in terms of the pressure exerted by a column of mercury of the stated height.

8.160. Reaction Time

Reaction time is 5 minutes unless otherwise specified.

8.170. Specific Gravity

Specific gravity is the weight of a substance in air at 25°C divided by the weight of an equal volume of water at the same temperature.

8.180. Temperatures

Temperatures are expressed in centigrade (Celsius) degrees, and all measurements are made at 25°C unless otherwise indicated. Where moderate heat is specified, any temperature not higher than 43°C (113°F) is indicated.

---

**Illustration of Rounding Numerical Values**

<table>
<thead>
<tr>
<th>Compendial Requirement</th>
<th>Unrounded Value</th>
<th>Rounded Result</th>
<th>Conforms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assay limit ≥98.0%</td>
<td>97.96%</td>
<td>98.0%</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>97.92%</td>
<td>97.9%</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>97.95%</td>
<td>98.0%</td>
<td>Yes</td>
</tr>
<tr>
<td>Assay limit ≤101.5%</td>
<td>101.55%</td>
<td>101.6%</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>101.46%</td>
<td>101.5%</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>101.45%</td>
<td>101.5%</td>
<td>Yes</td>
</tr>
<tr>
<td>Limit test ≤0.02%</td>
<td>0.025%</td>
<td>0.03%</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>0.015%</td>
<td>0.02%</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>0.027%</td>
<td>0.03%</td>
<td>No</td>
</tr>
<tr>
<td>Limit test ≤3 ppm</td>
<td>3.5 ppm</td>
<td>4 ppm</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>3.4 ppm</td>
<td>3 ppm</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>2.5 ppm</td>
<td>3 ppm</td>
<td>Yes</td>
</tr>
</tbody>
</table>
8.190. Time
Unless otherwise specified, rounding rules, as described in section 7.20, Rounding Rules, apply to any time specified.

8.200. Transfer
"Transfer" indicates a quantitative manipulation.

"Vacuum" denotes exposure to a pressure of less than 20 mm of mercury (2.67 kPas), unless otherwise indicated.

8.220. Vacuum Desiccator
"Vacuum desiccator" indicates a desiccator that maintains a low-moisture atmosphere at a reduced pressure of not more than 20 mm of mercury (2.67 kPas) or at the pressure designated in the individual monograph.

8.230. Water
8.230.10. Water as an Ingredient in an Official Product
As an ingredient in an official product, water meets the requirements of the appropriate water monograph in USP or NF.

When used in the manufacture of official substances, water may meet the requirements for drinking water as set forth in the regulations of the U.S. Environmental Protection Agency (potable water).

8.230.30. Water in a Compendial Procedure
When water is called for in a compendial procedure, the USP article Purified Water shall be used unless otherwise specified. Definitions for High-Purity Water and Carbon Dioxide-Free Water are provided in Containers—Glass (660). Definitions of other types of water are provided in Water for Pharmaceutical Purposes (1231).

8.240. Weights and Measures
In general, weights and measures are expressed in the International System of Units (SI) as established and revised by the Conférence générale des poids et mesures. For compendial purposes, the term "weight" is considered to be synonymous with "mass."

Molality is designated by the symbol $m$ preceded by a number that represents the number of moles of the designated solute contained in 1 kilogram of the designated solvent.

Molarity is designated by the symbol $M$ preceded by a number that represents the number of moles of the designated solute contained in an amount of the designated solvent that is sufficient to prepare 1 liter of solution.

Normality is designated by the symbol $N$ preceded by a number that represents the number of equivalents of the designated solute contained in an amount of the designated solvent that is sufficient to prepare 1 liter of solution.

Table of Symbols and Prefixes commonly employed for SI metric units and other units:

<table>
<thead>
<tr>
<th>Units</th>
<th>Symbol</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length</td>
<td></td>
<td></td>
</tr>
<tr>
<td>meter</td>
<td>m</td>
<td></td>
</tr>
<tr>
<td>centimeter</td>
<td>cm</td>
<td></td>
</tr>
<tr>
<td>millimeter</td>
<td>mm</td>
<td></td>
</tr>
<tr>
<td>micrometer</td>
<td>μm</td>
<td>Previously referred to as a micron</td>
</tr>
<tr>
<td>nanometer</td>
<td>nm</td>
<td>Previously the symbol μm (for millimicron) was used</td>
</tr>
<tr>
<td>Ångström</td>
<td>Å</td>
<td>Equal to 0.1 nm</td>
</tr>
<tr>
<td>Mass</td>
<td></td>
<td></td>
</tr>
<tr>
<td>kilogram</td>
<td>kg</td>
<td></td>
</tr>
<tr>
<td>gram</td>
<td>g</td>
<td></td>
</tr>
<tr>
<td>milligram</td>
<td>mg</td>
<td></td>
</tr>
<tr>
<td>Pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pascal</td>
<td>Pa</td>
<td></td>
</tr>
<tr>
<td>kilopascal</td>
<td>kPa</td>
<td></td>
</tr>
<tr>
<td>Volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>liter</td>
<td>L</td>
<td>1 L is equal to 1000 cm$^3$ (cubic centimeters)</td>
</tr>
<tr>
<td>deciliter</td>
<td>dL</td>
<td></td>
</tr>
<tr>
<td>milliliter</td>
<td>mL</td>
<td>1 mL is equal to 1 cm$^3$, sometimes referred to as cc</td>
</tr>
<tr>
<td>microliter</td>
<td>μL</td>
<td></td>
</tr>
<tr>
<td>Temperature</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celsius</td>
<td>°C</td>
<td></td>
</tr>
<tr>
<td>Amount of Substance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mole</td>
<td>mol</td>
<td>Historically referred to as gram-molecular weight or gram-atomic weight</td>
</tr>
<tr>
<td>millimole</td>
<td>mmol</td>
<td></td>
</tr>
<tr>
<td>micromole</td>
<td>μmol</td>
<td></td>
</tr>
<tr>
<td>femtomole</td>
<td>fmol</td>
<td></td>
</tr>
<tr>
<td>equivalent</td>
<td>Eq</td>
<td>Also referred to as gram-equivalent weight. It is used in the calculation of substance concentration in units of normality. This unit is no longer preferred for use in analytical chemistry or metrology.</td>
</tr>
<tr>
<td>milli-equivalent</td>
<td>mEq</td>
<td></td>
</tr>
<tr>
<td>osmole</td>
<td>Osmol</td>
<td>Osmotic pressure of a solution, related to substance concentration.</td>
</tr>
<tr>
<td>milliosmole</td>
<td>mOsmol</td>
<td></td>
</tr>
</tbody>
</table>